http://www.onemedplace.com/blog/wp-content/uploads/2009/10/access2.jpg
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company's pipeline.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/05/chemodrugs.jpg
All told, the Los Angeles-based company could have six to eight trials running simultaneously in the coming months.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2011/11/ceplene.jpg
Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
View ArticleThe Briefing Room: Novartis in India, Generic Drugs, Bird Flu, Sleep Apnea
In case you missed it, Monday featured a number of interesting developments in the world of healthcare and life sciences. Most notably, a seemingly rare patent defeat may harm Novartis' bottom line in...
View ArticleOneMedRadio: Del Mar Pharmaceuticals CEO Discusses the Public Market,...
Vancouver-based DelMar Pharmaceuticals [DMPI] is developing new drug candidates targeting orphan cancer indications representing market opportunities in the $100s of millions in North America and...
View ArticleSeeking Alpha: Cyclacel on the Verge of Becoming a Competitor for Big Pharma
Cyclacel Pharmaceuticals (CYCC) has been raising the eyebrows of many investors recently. This multi-marketed company has several potential medications in its pipeline, including: acute myeloid...
View ArticleOneMedForum Recap: Del Mar Pharmaceuticals
Delmar Pharmaceuticals (DMPI) is a clinical and early stage Oncologyl Company focused on developing and commercializing leading anti-cancer therapies in high impact orphan oncological indications...
View Article